摘要
目的探究TA方案化疗联合香菇多糖在治疗乳腺癌晚期患者中的临床应用效果。方法以近年来我院收治的乳腺癌患者63例为研究对象,采取随机数字表法分为两组,参照组31例实施TA方案化疗,研究组32例在参照组方法基础上联合使用香菇多糖,对比两组治疗效果。结果研究组CD4+/CD8+值高于参照组,生存质量评分改善率高于参照组(P<0.05)。结论采用TA方案化疗与香菇多糖联合治疗晚期乳腺癌,能够有效调节免疫力,改善患者的生存质量。
Objective To explore the clinical effect of TA regimen chemotherapy combined with lentinan in the treatment of patients with advanced breast cancer. Methods 63 breast cancer patients treated in our hospital in recent years were divided into two groups according to a random number table. 31 patients in the reference group was given chemotherapy with TA regimen, while 32 patients in the study group combined the use of lentinan. The effects of the two groups were compared. Results The CD4＋/CD8＋ ratio of study group was higher than that of reference group, and the improvement rate of quality of life score was higher than that of reference group （P 〈0.05）. Conclusion TA regimen combined with lentinan in the treatment of advanced breast cancer can effectively regulate immunity and improve the quality of life of patients.[
出处
《中国卫生标准管理》
2018年第1期84-86,共3页
China Health Standard Management
关键词
乳腺癌
晚期
TA化疗方案
香菇多糖
breast cancer
advanced stage
TA chemotherapy regimen
lentinan
